GlassScriptPhysician profile
Amy Miklos
NPI 1235501099
$3,419.85
in general payments reported to CMS, 2019-2025
27 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $520 · 2023: $502 · 2024: $1,558 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565 · Education: $20.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.18 |
| Education | $20.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.02 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.20 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $300.02 | 2023-2025 | Entyvio |
| Ardelyx, INC. | $277.93 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $249.52 | 2021-2022 | |
| Qol Medical, LLC | $244.70 | 2023-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $219.20 | 2024 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $172.15 | 2024-2025 | Voquezna |
| Celgene Corporation | $103.45 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $99.43 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $82.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $80.99 | 2024 | |
| Genzyme Corporation | $68.22 | 2022 | |
| Madrigal Pharmaceuticals | $63.94 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $53.55 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $52.96 | 2023-2024 | Ocaliva |
| Gilead Sciences, INC. | $42.12 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $40.21 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $24.25 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $22.92 | 2023 | |
| Fresenius Kabi USA, LLC | $22.57 | 2023 | |
| Merck Sharp & Dohme LLC | $22.10 | 2024 | Dificid |
| Celltrion USA INC. | $20.34 | 2024 | Zymfentra |
| Intra-Sana Laboratories | $20.13 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lucid Diagnostics INC. | $17.46 | 2024 | |
| Evoke Pharma, INC. | $16.82 | 2023 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Miklos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.